Targeting a cancer-specific epitope of the epidermal growth factor receptor in triple-negative breast cancer

Journal of the National Cancer Institute

Volumn 108, Issue 8, 2016, Pages

  Simon, Nathan ^a   Antignani, Antonella ^a   Sarnovsky, Robert ^a   Hewitt, Stephen M ^a   FitzGerald, David ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

806PE 38; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPITOPE; EXOTOXIN; IMMUNOTOXIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; BACTERIAL TOXIN; DRUG CARRIER; IMMUNOLOGIC FACTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; RECOMBINANT PROTEIN; TOXA PROTEIN, PSEUDOMONAS AERUGINOSA; VIRULENCE FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER CELL LINE; CANCER INHIBITION; CANCER SIZE; CANCER SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENCY; FEMALE; GENE FUSION; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MISFOLDING; PSEUDOMONAS AERUGINOSA; SYSTEMIC THERAPY; TRIPLE NEGATIVE BREAST CANCER; ANIMAL; CANCER TRANSPLANTATION; CELL SURVIVAL; DRUG EFFECTS; GENETICS; IMMUNOLOGY; NUDE MOUSE; PATHOLOGY; SURVIVAL RATE; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE; TUMOR VOLUME;

ADP RIBOSE TRANSFERASES; ANIMALS; BACTERIAL TOXINS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG CARRIERS; EPITOPES; ERBB RECEPTORS; EXOTOXINS; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTOXINS; MICE; MICE, NUDE; MOLECULAR TARGETED THERAPY; NEOPLASM TRANSPLANTATION; RECOMBINANT PROTEINS; SURVIVAL RATE; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR BURDEN; VIRULENCE FACTORS;

EID: 84992322814     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djw028     Document Type: Article

References (52)

1. Dent R, Trudeau M, Pritchard KI, et al. Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence. Clin Cancer Res. 2007; 13(15):4429-4434.
2. Boyle P. Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol. 2012; 23: vi7-vi12.
3. Liedtke C, Mazouni C, Hess KR, et al. Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer. J Clin Oncol. 2008; 26(8):1275-1281.
4. Shah SP, Roth A, Goya R, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012; 486(7403):395-399.
5. Abramson VG, Lehmann BD, Ballinger TJ, et al. Subtyping of triple-negative breast cancer: Implications for therapy. Cancer. 2015; 121(1):8-16.
6. Tung N, Gaughan E, Hacker MR, et al. Outcome of triple negative breast cancer: comparison of sporadic and BRCA1-associated cancers. Breast Cancer Res Treat. 2014; 146(1):175-182.
7. Foulkes WD, Smith IE, Reis-Filho JS. Triple-Negative Breast Cancer. N Engl J Med. 2010; 363(20):1938-1948.
8. Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol. 2007; 8(3):235-244.
9. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012; 12(4):278-287.
10. Park HS, Jang MH, Kim EJ, et al. High EGFR gene copy number predicts poor outcome in triple-negative breast cancer. Mod Pathol. 2014; 27(9):1212-1222.
11. Liu D, He J, Yuan Z, et al. EGFR expression correlates with decreased disease free survival in triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Med Oncol. 2012; 29(2):401-405.
12. Mazor Y, Noy R, Wels WS, et al. chFRP5-ZZ-PE38, a large IgG-toxin immunoconjugate outperforms the corresponding smaller FRP5(Fv)-ETA immunotoxin in eradicating ErbB2-expressing tumor xenografts. Cancer Lett. 2007; 257(1):124-135.
13. Mahmud H, Dalken B, Wels WS. Induction of programmed cell death in ErbB2/HER2-expressing cancer cells by targeted delivery of apoptosis-inducing factor. Mol Cancer Ther. 2009; 8(6):1526-1535.
14. Krop IE, LoRusso P, Miller KD, et al. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2012; 30(26):3234-3241.
15. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012; 367(19):1783-1791.
16. Luwor RB, Johns TG, Murone C, et al. Monoclonal Antibody 806 Inhibits the Growth of Tumor Xenografts Expressing Either the de2-7 or Amplified Epidermal Growth Factor Receptor (EGFR) but not Wild-Type EGFR. Cancer Res. 2001; 61(14):5355-5361.
17. Jungbluth AA, Stockert E, Huang HJ, et al. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc Natl Acad Sci USA. 2003; 100(2):639-644.
18. Johns TG, Stockert E, Ritter G, et al. Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene. Int J Cancer. 2002; 98(3):398-408.
19. Garrett TPJ, Burgess AW, Gan HK, et al. Antibodies specifically targeting a locally misfolded region of tumor associated EGFR. Proc Natl Acad Sci USA. 2009; 106(13):5082-5087.
20. Johns TG, Adams TE, Cochran JR, et al. Identification of the Epitope for the Epidermal Growth Factor Receptor-specific Monoclonal Antibody 806 Reveals That It Preferentially Recognizes an Untethered Form of the Receptor. J Biol Chem. 2004; 279(29):30375-30384.
21. Bardelli A, Janne PA. The road to resistance: EGFR mutation and cetuximab. Nat Med. 2012; 18(2):199-200.
22. Li S, Schmitz KR, Jeffrey PD, et al. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell. 2005; 7(4):301-311.
23. Scott AM, Lee F-T, Tebbutt N, et al. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci USA. 2007; 104(10):4071-4076.
24. Li D, Ji H, Zaghlul S, et al. Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas. J Clin Invest. 2007; 117(2):346-352.
25. Frankel AE, Houston LL, Issell BF, et al. Prospects for immunotoxin therapy in cancer. Annu Rev Med. 1986; 37:125-142.
26. Pastan I, Hassan R, Fitzgerald DJ, et al. Immunotoxin therapy of cancer. Nat Rev Cancer. 2006; 6(7):559-565.
27. Hassan R, Miller AC, Sharon E, et al. Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Sci Transl Med. 2013; 5(208):208ra147.
28. Kreitman RJ, Tallman MS, Robak T, et al. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia J Clin Oncol. 2012; 30(15):1822-1828.
29. Chaudhary VK, FitzGerald DJ, Adhya S, et al. Activity of a recombinant fusion protein between transforming growth factor type alpha and Pseudomonas toxin. Proc Natl Acad Sci USA. 1987; 84(13):4538-4542.
30. Ahmed N, Brawley VS, Hegde M, et al. Human Epidermal Growth Factor Receptor 2 (HER2)-Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. J Clin Oncol. 2015; 33(15): 1688-1696.
31. Schonfeld K, Sahm C, Zhang C, et al. Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2/HER2-Specific Chimeric Antigen Receptor. Mol Ther. 2015; 23(2):330-338.
32. Li B, Meng Y, Zheng L, et al. Bispecific Antibody to ErbB2 Overcomes Trastuzumab Resistance through Comprehensive Blockade of ErbB2 Heterodimerization. Cancer Res. 2013; 73(21):6471-6483.
33. Dickler MN, Cobleigh MA, Miller KD, et al. Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast Cancer Res Treat. 2009; 115(1):115-121.
34. Sergina NV, Rausch M, Wang D, et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature. 2007; 445(7126):437-441.
35. Baselga J, Gomez P, Greil R, et al. Randomized Phase II Study of the Anti Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer. J Clin Oncol. 2013; 31(20):2586-2592.
36. Lee H-J, Zhuang G, Cao Y, et al. Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells. Cancer Cell. 2014; 26(2):207-221.
37. Johns TG, Perera RM, Vernes SC, et al. The Efficacy of Epidermal Growth Factor Receptor-Specific Antibodies against Glioma Xenografts Is Influenced by Receptor Levels, Activation Status, and Heterodimerization. Clin Cancer Res. 2007; 13(6):1911-1925.
38. Petrocca F, Altschuler G, Tan Shen M, et al. A Genome-wide siRNA Screen Identifies Proteasome Addiction as a Vulnerability of Basal-like Triple Negative Breast Cancer Cells. Cancer Cell. 2013; 24(2):182-196.
39. Adams KW, Cooper GM. Rapid Turnover of Mcl-1 Couples Translation to Cell Survival and Apoptosis. J Biol Chem. 2007; 282(9):6192-6200.
40. Du X, Youle RJ, FitzGerald DJ, et al. Pseudomonas Exotoxin A-Mediated Apoptosis Is Bak Dependent and Preceded by the Degradation of Mcl-1. Mol Cell Biol. 2010; 30(14):3444-3452.
41. Hassan R, Sharon E, Thomas A, et al. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for frontline therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125. Cancer. 2014; 120(21):3311-3319.
42. Mattoo AR, Pastan I, FitzGerald D. Combination Treatments with the PKC Inhibitor, Enzastaurin, Enhance the Cytotoxicity of the Anti-Mesothelin Immunotoxin, SS1P. PLoS ONE. 2013; 8(10):e75576.
43. Traini R, Ben-Josef G, Pastrana DV, et al. ABT-737 overcomes resistance to immunotoxin-mediated apoptosis and enhances the delivery of pseudomonas exotoxin-based proteins to the cell cytosol. Mol Cancer Ther. 2010; 9(7):2007-2015.
44. Onda M, Ghoreschi K, Steward-Tharp S, et al. Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts. J Immunol. 2014; 193(1):48-55.
45. Mazor R, Eberle JA, Hu X, et al. Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes. Proc Natl Acad Sci U S A. 2014; 111 (23):8571-8576.
46. Liu W, Onda M, Lee B, et al. Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes. Proc Natl Acad Sci U S A. 2012; 109(29):11782-11787.
47. Barrett MT, Anderson KS, Lenkiewicz E, et al. Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer. Oncotarget. 2015; 6(28):26483-26493.
48. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR Mutation and Resistance of Non-Small-Cell Lung Cancer to Gefitinib. N Engl J Med. 2005; 352(8):786-792.
49. Berstad MB, Cheung LH, Berg K, et al. Design of an EGFR-targeting toxin for photochemical delivery: in vitro and in vivo selectivity and efficacy. Oncogene. 2015; 34(44):5582-5592.
50. Shaw JP, Akiyoshi DE, Arrigo DA, et al. Cytotoxic properties of DAB486EGF and DAB389EGF, epidermal growth factor (EGF) receptor-targeted fusion toxins. J Biol Chem. 1991; 266(31):21118-21124.
51. Oh S, Stish BJ, Sachdev D, et al. A Novel Reduced Immunogenicity Bispecific Targeted Toxin Simultaneously Recognizing Human Epidermal Growth Factor and Interleukin-4 Receptors in a Mouse Model of Metastatic Breast Carcinoma. Clin Cancer Res. 2009; 15(19):6137-6147.
52. Ogata M, Pastan I, FitzGerald D. Analysis of Pseudomonas exotoxin activation and conformational changes by using monoclonal antibodies as probes. Infect Immun. 1991; 59(1):407-414.